Analysts have given Sage Therapeutics, Inc. (NASDAQ:SAGE) a consensus rating of “Hold.”
According to information made available by Bloomberg Ratings, the fifteen rating agencies presently keeping an eye on Sage Therapeutics, Inc. (NASDAQ: SAGE) have collectively assigned …